Niowave

Executive Summary

Niowave, founded in 2005 and based in Lansing, Michigan, is a critical player in the medical radioisotope supply chain, focusing on the production of Actinium-225 (Ac-225), a key isotope for next-generation targeted alpha therapies against cancer. The company addresses a significant market gap: the current supply of Ac-225 is insufficient and unreliable, hindering the development and commercialization of promising radiopharmaceuticals. Niowave's proprietary technology enables scalable, domestic production, positioning it as a vital partner for pharmaceutical companies developing alpha-emitting radiopharmaceuticals. With growing demand from clinical trials and potential FDA approvals, Niowave's ability to deliver consistent, high-purity Ac-225 is crucial. In the coming quarters, Niowave is expected to advance its production capacity and secure strategic partnerships. Potential catalysts include a major supply agreement with a leading radiopharma developer, regulatory clearance for its production facility, or a significant funding round to scale operations. The company's strong intellectual property portfolio and government support (e.g., DOE initiatives) enhance its competitive moat. While challenges such as regulatory hurdles and competition exist, Niowave's focus on a high-demand, bottleneck isotope makes it a compelling investment opportunity in the radiopharmaceutical ecosystem.

Upcoming Catalysts (preview)

• Q3 2026Major Supply Agreement with Radiopharma Developer65% success
• Q4 2026GMP Certification for Ac-225 Production Facility70% success
• Q2 2026Series B Funding Round75% success